Skip to main content

Table 2 Grade 3–4 adverse events occurring in ≥3 % of the safety population

From: Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

Adverse events

Safety population (n = 80)

Patient with ≥1 grade 3–4 adverse event

48 (60.0)

Neutropenia

16 (20.0)

Decreased neutrophil counta

11 (13.8)

Anemia

9 (11.3)

Pneumonia

7 (8.8)

Decreased white blood cell count

6 (7.5)

Leukopenia

5 (6.3)

Thrombocytopenia

5 (6.3)

Upper respiratory tract infection

5 (6.3)

Fatigue

4 (5.0)

Decreased platelet count

4 (5.0)

Hypocalcemia

3 (3.8)

Hypokalemia

3 (3.8)

  1. All values n (%)
  2. aDecreased neutrophil count refers to a fall in absolute neutrophil count since the last cycle, but not a low enough count to be considered neutropenia